New Technology– category –
-
Park Systems Invests in Advanced Nanoscale Metrology Portfolio to Drive Next-Gen 3D Packaging and Logic Research
PR Newswire USA Overview Park Systems, a global leader in AFM and nanoscale metrology, announced a strategic investment in its advanced metrology portfolio for 3D packaging and logic research. This initiative aims to accelerate the evolu... -
FAPI-46 Theranostic Agent Shows Promising Survival Benefits in Glioblastoma Peripheral Models, But Brain-Blood Barrier Permeation Remains a Challenge
Journal of Nuclear Medicine USA Overview A study on glioblastoma evaluated FAP inhibitor (FAPI)-46 as a theranostic agent targeting fibroblast activation protein (FAP). In vivo, diagnostic [68Ga]Ga-FAPI-46 demonstrated high tumor uptake,... -
Non-Viral CRISPR/Cas9 HDR Platform Enables Stable Genetic Engineering of Solid Tumor Models, Overcoming Viral Vector Challenges
bioRxiv (Preprint) USA Overview This preprint reports research on a non-viral CRISPR/Cas9 Homology-Directed Repair (HDR) platform for stable genetic engineering of solid tumor models. This approach enables precise genome modification and... -
FDA Expedited Pathway Guide: Strategic Selection of Fast Track, Breakthrough Therapy, and RMAT
Boyd Consultants USA Overview The FDA offers several expedited programs to accelerate innovative drug development, including Fast Track, Breakthrough Therapy, and Regenerative Medicine Advanced Therapy (RMAT). This article outlines the d... -
Allogeneic BCMA CAR T Therapy CB-011 Achieves Deep Responses and Confirms Immune Cloaking in Multiple Myeloma Phase 1 Trial
The ASCO Post USA Overview CB-011, the first allogeneic anti-BCMA CAR T-cell therapy incorporating immune cloaking technology, achieved a high overall response rate (ORR) in its Phase 1 CaMMouflage trial for relapsed/refractory heavily p... -
Caribou Biosciences’ Off-the-Shelf Allogeneic CAR T Vispa-cel Shows Superior PFS to Approved Autologous CAR T Therapies in Lymphoma Phase 1
Fierce Biotech USA Overview Caribou Biosciences announced promising median progression-free survival (PFS) data from its Phase 1 clinical trial of vispacabtagene regedleucel (vispa-cel), an off-the-shelf allogeneic CAR T-cell therapy for... -
Cellectis’ Lasme-cel Receives FDA RMAT Designation as First Allogeneic CAR T in Pivotal Trial for R/R B-ALL, EHA Data Confirms Efficacy
Stock Titan (Cellectis SEC Filing) USA Overview Cellectis announced that its CD22-targeting allogeneic CAR T-cell therapy candidate, lasme-cel (UCART22), has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA... -
FreakOut Launches HAWK, an AI Agent for Autonomous Social Ad Operations, Automating Workflow from RFP to KPI Monitoring
The Agile Brand Guide® (original source: MarTech Series) Japan Overview Ad tech provider FreakOut, Inc. announced the launch of HAWK, an AI agent designed to autonomously execute daily social media ad operational workflows. HAWK covers e... -
ASMC 2026 Outlines Practical Roadmap for AI in Semiconductor Manufacturing, Emphasizing Core Pillars: Physical Fab, Digital Twin, and Enterprise AI Platform Construction
ASMC USA Overview The 2026 ASMC (Semiconductor Manufacturing Conference) outlined a practical roadmap for semiconductor manufacturers to move beyond experimental AI adoption to scalable, value-driven implementation. Success in AI mandate... -
AI in Drug Discovery: Investment Surges Amidst Persistent Questions on Validation, Reproducibility, and Real-World Applicability
Drug Target Review UK Overview AI has attracted substantial investment in drug discovery, yet significant questions persist regarding its validation, reproducibility, and real-world applicability. A recent 'Beyond the Lab' report feature...
